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Abstract: Pituitary adenylate cyclase-activating polypeptide (PACAP) is a pleiotropic peptide and a well known strong 
neuroprotectant in various neuronal conditions. PACAP has some receptors and it acts via these receptors. PACAP type 1 
receptor (PAC1R) is known as the main receptor of PACAP in neuronal damages. On the other hand, the expression and 
localization of PAC1R have not been elicited well in traumatic brain injury (TBI). In this study, the expression and the 
cellular localization of PAC1R were investigated immunohistochemically after TBI in mouse controlled cortical impact 
(CCI) model. The PAC1R positive cells were expressed from 3 h in the peri-contusional area and observed to 7days after 
the TBI. Using double-immunohistochemistry, the PAC1R immunopositive cells were co-localized with the microglia on 
1day and with microglia and astrocyte on 7 days after TBI. These results suggest that PACAP and PAC1R might play an 
important role in traumatic brain injury as well as other conditions. 
Keywords: Pituitary adenylate cyclase-activating polypeptide, PACAP type 1 receptor, traumatic brain injury. 
INTRODUCTION 
 Traumatic brain injury (TBI) is a critical condition in the 
field of emergency medicine. In the treatment of TBI, the 
secondary brain damage originated from the complicated 
factors, such as neuroinflammation, brain edema and secon-
dary brain ischemia, has been considered as main targets in 
neurocritical care. In spite of the advance in the recent re-
search, the treatment outcome of TBI has not still improved. 
In the United States, TBI accounts for about 40% of all acute 
deaths, and the mortality of severe TBI is 51%[1]. In Japan, 
TBI is one of the major causes of mortality in the younger 
population. 
 Pituitary adenylate cyclase-activating polypeptide 
(PACAP) is a neuropeptide that was first isolated from ovine 
hypothalamic extracts in 1989, which belongs to the se-
cretin-glucagon vasoactive intestinal peptide (VIP) family, 
and it exists in two types of amino acid chains, namely a 38 
amino acid chain (PACAP38), and a 27 amino acid chain 
(PACAP27), which share the same N-terminal amino acids. 
Both PACAP38 and PACAP27 have similar uniformity to 
VIP in their amino acid chains. It has been reported that 
PACAP prevents from neuron strongly in various neuronal 
injuries [2, 3]. 
 PACAP have 3 types of receptors, PACAP type 1 recep-
tor (PAC1R), VIP type 1 receptor (VPAC1R), and VIP  type  
 
 
*Address correspondence to this author at the Department of Emergency 
and Critical Care Medicine, School of Medicine, Showa University, Hata-
nodai 1-5-8, Shinagawa-ku, Tokyo, Japan; Tel: +81 3 3784 8103; Fax: +81 
3 3784 6815; E-mail: kdop@med.showa-u.ac.jp 
2 receptor (VPAC2R). These receptors are G protein-
coupled receptors with seven transmembrane domains [2, 3]. 
It is thought that PAC1R is a main receptor in the neuropro-
tective effect of PACAP in these receptors [3]. PAC1R binds 
PACAP38 and PACAP27 with a high affinity, but binds VIP 
with a 1,000-fold lower affinity [3]. Many PACAP studies 
which related to cerebral ischemia has been reported. On the 
other hand, a few studies correlated with TBI have been re-
ported [4, 5], but the PAC1R expression after TBI in mice 
remains unclear. 
 In this study, we investigate the PAC1R expressions and 
the cell identification of the PAC1R expressed cellsby im-
munohistochemical studies. 
MATERIALS AND METHODS 
Animal 
 All experimental procedures involving the handling of 
the animals were approved by the Institutional Animal Care 
and Use Committee of Showa University (regulation nos. 
04093, 04096, 03020, and 02098). 
 Adult male C57BL mice (20-25g; Saitama Experimental 
Animal Center, Saitama, Japan) were housed in a tempera-
ture- and light-controlled room (lights on at 0600 and off at 
1800) and supplied with standard laboratory chow and water 
ad libitum. 
Production of the PAC1R Antibody 
 The primary antisera were raised in rabbits against a syn-
thetic peptide that corresponded to Cys
34
 to Leu
47
 of the 
mouse PAC1R, which is located in the amino-terminal ex-
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tracellular domain of all the splice variants [6-8]. The syn-
thetic peptide (CLERIQRANDLMGL) was conjugated to 
keyhole limpet hemocyanin and then it was injected subcu-
taneously into the rabbits. The antisera were purified by af-
finity chromatography using a synthetic peptide conjugated-
Affi-Gel 10 column (Pierce Chemical Co., Rockford, IL). 
Surgical Procedure 
 Mice undergoing surgery were maintained in the supine 
position under anesthesia with 2% sevoflurane in 70% N2O 
and 30% O2 through a nose cone, shaved, mounted in a 
stereotactic frame and subjected to CCI using a Lighthall 
stroke-constrained pneumatic compression device adapted 
for mice [9, 10]. Following a midline incision to expose the 
skull, a 4-mm craniotomy was made lateral to the sagittal 
suture, and centered between lambda and bregma. The skull 
at the craniotomy site was removed with a dural incision. 
The exposed cortex was injured using a pneumatically con-
trolled impactor device as described previously [11, 12]. The 
impactor containing a 3-mm diameter flat tip compressed the 
cortex at a velocity of 5.82 m/s, duration of 47 ms, depth of 
1.2 mm, and with a driving pressure of 73 psi. After surgery, 
the injured area was covered with the dura. Following the 
suturing of the skin, the animals were placed in an incubator 
(37°C) until the mice regained consciousness (determined by 
the return of the righting reflex and increased mobility) in 
order to prevent hypothermia. 
Histology 
 Mice were anesthetized with sodium pentobarbital 
(50mg/kg, ip) at 0, 3, 6, 12 h, 1, 2, 4 or 7 days afterTBI, and 
brains were fixed by perfusion with saline followed by 2% 
paraformaldehyde in 50 mM phosphate buffer(n=4-5). Af-
ter postfixation, the brain tissues containing injured area 
were embedded in OCT compound after immersion in 20% 
sucrose for cytoprotection as a frozen section. The paraffin 
sections (thickness 4 μm) were used for immunostaining. 
Single Immunostaining of PAC1R 
 For immunoperoxidase labeling, the cryostat sections 
were incubated in 0.3% hydrogen peroxide (H2O2) to block 
endogenous peroxidase activity and incubated in phosphate-
buffered saline (PBS) containing 5% normal horse serum 
(NHS) to block any nonspecific reaction. The sections were 
incubated in rabbit anti-PAC1R antibody (1:200) at 4°C 
overnight. Antibody detection was carried out by incubating 
the slices with biotinylated goat anti-rabbit IgG (Vector, 
Burlingame, USA) as a secondary antibody for 120 min, 
followed by Vectastain ABC (Vector) for 60 min, and then 
with stable 3,3’-diaminobenzidine complex (DAB; Vector). 
Double Immunostaining for Cell Identification 
 The samples of 1 and 7days after TBI were used to cell 
identification (n=3). The brain sections were blocked in 5% 
NHS (for GFAP, CD11b, NeuN, and PAC1R) for 1 h at 
room temperature. The sections were then immunostained 
using the following primary antibodies: monoclonal mouse 
anti-GFAP at a 1:1000 dilution; monoclonal rat anti-CD11b 
at a 1:500 dilution; monoclonal mouse anti-neuronal nuclei 
at a 1:1000 dilution; and 2 μg/ml of affinity-purified rabbit 
polyclonal anti-PAC1R antibody. 
 The above primary antibodies were diluted in 5% NHS 
(for GFAP, CD11b, NeuN, and PAC1R) and the sections 
were incubated with them at 4°C overnight. The sections 
were then rinsed and incubated with secondary antibodies for 
120 min at room temperature. Alexa 546-conjugated goat 
anti-mouse IgG at a 1:400 dilution (for GFAP and NeuN), 
biotinylated anti-rat IgG at a 1:200 dilution (for CD11b), and 
Alexa 546-conjugated goat anti-rabbit IgG (Molecular 
Probes) at a 1:400 dilution (for PAC1R) were used as the 
secondary antibodies. For CD11b immunostaining, the sec-
tions were rinsed and further incubated with a 1:400 dilution 
of Alexa 546-labeled streptavidin (Molecular Probes) for 30 
min at room temperature. For double immunostaining for 
GFAP and PAC1R, Alexa 488-conjugated goat anti-mouse 
IgG (Molecular Probes) at a 1:400 dilution was used for 
GFAP. Nuclear staining was performed by 4,6-diamidine-2-
phenylindole dihydrochloride (DAPI, 1:10,000; Roche Di-
agnostics, IN, USA) for 5 min. Both fluorescence and the 
immunolabeling were detected using a confocal laser micro-
scope (AX-10, Zeiss, Germany). 
RESULTS 
PAC1R Expressions After Traumatic Brain Injury 
 In 0 h after TBI (Fig. 1A, B), the PAC1R expression was 
slightly observed in the cortex. 
 After 3 h after TBI, the PAC1R positive cells were ob-
served more clearly in the peri-contusional area. The PAC1R 
immunoreactivity and the numbers of immunopositive cells 
were gradually increased (the photos of 6, 12h and 2 days 
were not shown) (Fig. 1)). Morphologically, small cells like 
microglia were distributed in the peri-contusional area in 3 h 
after injury (Fig. 1D). On day 4 after injury, large cells like 
astrocyte were also expressed with small cells (Fig. 1G, H). 
Except for peri-contusional area including the deep white 
matter and the contra-lateral brain, the strong immunoreac-
tions of PAC1R were not observed. 
Identification of the PAC1R-Positive Cells 
 We observed PAC1R positive cells in peri-contusional 
area in both samples. On day 1after TBI, the PAC1R positive 
cells were obviously co-localized with microglia (Fig. 2). On 
day 7, PAC1R was not only expressed in microglia but also 
in the astrocyte (Fig. 3). Neuron was not co-localized with 
the PAC1R positive cellsin both samples (Figs. 2, 3). 
DISCUSSION 
 In our previous study, we have examined the PAC1R 
expressions and the cellular localization after TBI to estimate 
the kinetics of PAC1R. The PAC1R positive cells were 
closely distributed to the peri-contusional area and expressed 
from the early phase after the insult. Thereafter, PAC1R 
positive cells were observed in this area up to 7 days after 
TBI. We also performed cell identification of PAC1R im-
munopositive cells. The PAC1R expressed in microgliaon 
day 1 after TBI. On day 7
th
 after TBI, PAC1R was also ex-
pressed in astrocyte. 
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Fig. (1). Light photomicrographs of the time course of the PAC1R positive cells at 0 h (A, B), 3 h (C, D), 1 day (E, F), 4 days (G, H), and 7 
days (I, J) after traumatic brain injury. PAC1R immunoreactivity was detected in the perifocal area of the trauma lesion at 3 h after brain 
injury and it was expressed until 7 days post trauma. Boxed areas in A, C, E, G and I indicated the areas magnified in B, D, F and H. Over-
view of the injured region at 7 days after insult was shown (K). Scale bars=100 μm. 
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 We also previously reported that PACAP prevents post-
ischemic neuronal cell death. PACAP injection into the in-
tracerebroventricular (i.c.v.) space induces Interleukin-6 (IL-
6) secretion in cerebrospinal fluid and inhibits c Jun N-
terminal kinase (JNK) and p38 phosphorylation in the hippo-
campus in an after-cardiac-arrest rat model [2,13]. It was 
also shown that endogenous PACAP plays a critical role in 
the prevention of ischemic neuronal cell death in vivo and 
that PACAP suppresses cytochrome c release by means of 
the regulation of bcl-2 in mitochondria. PACAP prevents 
cerebellar granule neurons from apoptotic cell death through 
a protein kinase A (PKA)/ protein kinase C (PKC)-
dependent inhibition of caspase-3 activity [14]. PACAP 
regulates phosphorylated extracellular signal-regulated 
kinase (ERK) directly, and phosphorylated signal transducer 
and activator of transcription (STAT) 3 indirectly by the 
generation of IL-6 through PAC1R in neurons [15]. Those 
signaling pathways leading to apoptosis are inhibited by 
PACAP i.c.v. administration. PAC1R is actively expressed 
in different neuroepithelia from the early developmental 
stages and is expressed in various brain regions during pre-
natal and postnatal development, and is widely distributed in 
the embryonic central and peripheral nervous system[16, 
17]. It is therefore well-recognized that PACAP have plei-
otropic functions in the central nervous system. 
 
Fig. (2). Double immunostaining of PAC1R with cell markers in the perifocal area of the injured brain at 1 day after the traumatic brain in-
jury. Immunostaining was carried out using antibodies for PAC1R (shown in green) together with CD11-b (B), GFAP (E), NeuN (H) as 
microglia, astrocytes, and neuron markers (shown in red), respectively. Microglia-like CD11-b immunoreactive cells were co-labeled with 
PAC1R immunoreactivity (C). In the merged images, blue is DAPI staining as counterstaining of nuclei. Scale bars=50 μm. 
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 In the current study, PAC1R was expressed not only in 
the astrocyte, but also in the microglia from the early phase 
after the TBI.Previous studies reported the amount of 
PAC1R mRNA to increase after ischemia from day 1 to day 
3 [18] and the PAC1R-like immunoreactivity in the reactive 
astrocytes was intensified until day 7 after the forebrain 
ischemia [19]. Suzuki et al. reported that PAC1R-like im-
munoreactivity was observed in the reactive astrocytes at day 
5after a stab wound, whereas no PAC1R-like immunoreac-
tivity was detected in the reactive astrocyte at 48 h post sur-
gery [5]. In our past study, using ischemic model, PAC1R 
expression was also observed in neuron [15]. The diversity 
of PAC1R immunoreactivity might be originated in the dif-
ferences of animal species and pathophysiolosies. Further 
experiments will be needed to clarify this point. 
CONCLUSION 
 Traumatic brain injury affected the PAC1R expression in 
the microglia and astrocyte in the peri-contusional area. 
These data suggest that PACAP may play an important role 
involving neuroprotective effect in the complicated patho-
physiology of traumatic brain injury. 
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Fig. (3). Double immunostaining of PAC1R with cell markers in the perifocal area of injured brain at 7 days after traumatic brain injury. 
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were co-labeled with PAC1R immunoreactivity (C, F). In the merged images, blue is DAPI staining as counterstaining of nuclei. Scale 
bars=50 μm. 
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